MX2022010664A - Materiales y métodos para modular una respuesta inmunitaria. - Google Patents

Materiales y métodos para modular una respuesta inmunitaria.

Info

Publication number
MX2022010664A
MX2022010664A MX2022010664A MX2022010664A MX2022010664A MX 2022010664 A MX2022010664 A MX 2022010664A MX 2022010664 A MX2022010664 A MX 2022010664A MX 2022010664 A MX2022010664 A MX 2022010664A MX 2022010664 A MX2022010664 A MX 2022010664A
Authority
MX
Mexico
Prior art keywords
methods
antibodies
modulating
materials
immune response
Prior art date
Application number
MX2022010664A
Other languages
English (en)
Spanish (es)
Inventor
Sanjaya Singh
Rajkumar Ganesan
Iqbal S Grewal
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/031749 external-priority patent/WO2020227457A1/en
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2022010664A publication Critical patent/MX2022010664A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2022010664A 2020-02-27 2021-02-26 Materiales y métodos para modular una respuesta inmunitaria. MX2022010664A (es)

Applications Claiming Priority (46)

Application Number Priority Date Filing Date Title
US202062982478P 2020-02-27 2020-02-27
US202062982664P 2020-02-27 2020-02-27
US202062982602P 2020-02-27 2020-02-27
US202062982574P 2020-02-27 2020-02-27
US202062982462P 2020-02-27 2020-02-27
US202062982374P 2020-02-27 2020-02-27
US202062982469P 2020-02-27 2020-02-27
US202062982492P 2020-02-27 2020-02-27
US202062982548P 2020-02-27 2020-02-27
US202062982505P 2020-02-27 2020-02-27
US202062982525P 2020-02-27 2020-02-27
US202062982669P 2020-02-27 2020-02-27
US202062982535P 2020-02-27 2020-02-27
US202062982591P 2020-02-27 2020-02-27
US202062989052P 2020-03-13 2020-03-13
US202062989042P 2020-03-13 2020-03-13
US202062988996P 2020-03-13 2020-03-13
US202062989075P 2020-03-13 2020-03-13
US202062989002P 2020-03-13 2020-03-13
US202062989006P 2020-03-13 2020-03-13
US202062989036P 2020-03-13 2020-03-13
US202062989024P 2020-03-13 2020-03-13
US202062989045P 2020-03-13 2020-03-13
US202062989068P 2020-03-13 2020-03-13
US202062989010P 2020-03-13 2020-03-13
US202062989057P 2020-03-13 2020-03-13
US202062989027P 2020-03-13 2020-03-13
US202062989018P 2020-03-13 2020-03-13
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity
US202063074925P 2020-09-04 2020-09-04
US202063074962P 2020-09-04 2020-09-04
US202063074676P 2020-09-04 2020-09-04
US202063074700P 2020-09-04 2020-09-04
US202063074854P 2020-09-04 2020-09-04
US202063074903P 2020-09-04 2020-09-04
US202063074893P 2020-09-04 2020-09-04
US202063074937P 2020-09-04 2020-09-04
US202063074655P 2020-09-04 2020-09-04
US202063074759P 2020-09-04 2020-09-04
US202063074946P 2020-09-04 2020-09-04
US202063074749P 2020-09-04 2020-09-04
US202063074839P 2020-09-04 2020-09-04
US202063074735P 2020-09-04 2020-09-04
US202063112475P 2020-11-11 2020-11-11
US202063112462P 2020-11-11 2020-11-11
PCT/US2021/019766 WO2021173896A1 (en) 2020-02-27 2021-02-26 Materials and methods for modulating an immune response

Publications (1)

Publication Number Publication Date
MX2022010664A true MX2022010664A (es) 2022-11-30

Family

ID=77492135

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010664A MX2022010664A (es) 2020-02-27 2021-02-26 Materiales y métodos para modular una respuesta inmunitaria.

Country Status (10)

Country Link
US (1) US20220306739A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023515199A (cg-RX-API-DMAC7.html)
KR (1) KR20220147631A (cg-RX-API-DMAC7.html)
CN (1) CN115484981A (cg-RX-API-DMAC7.html)
AU (1) AU2021225870A1 (cg-RX-API-DMAC7.html)
CA (1) CA3173268A1 (cg-RX-API-DMAC7.html)
IL (1) IL295897A (cg-RX-API-DMAC7.html)
MX (1) MX2022010664A (cg-RX-API-DMAC7.html)
TW (1) TW202144415A (cg-RX-API-DMAC7.html)
WO (1) WO2021173896A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
MX386714B (es) 2015-01-27 2025-03-11 Lava Therapeutics N V Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
JP7457007B2 (ja) 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用CD1d免疫グロブリン
CN119954959A (zh) 2019-03-11 2025-05-09 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
JP7686571B2 (ja) * 2019-05-08 2025-06-02 ヤンセン バイオテツク,インコーポレーテツド T細胞媒介性免疫を調節するための材料及び方法
EP4076526A4 (en) 2019-12-17 2024-07-03 The Board Of Regents Of The University Of Texas System Novel ddr1 antibodies and uses thereof
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
IL301242A (en) * 2020-09-11 2023-05-01 Janssen Biotech Inc Multi-specific immune targeting molecules and uses thereof
UY39415A (es) 2020-09-11 2022-03-31 Janssen Biotech Inc Métodos y composiciones para modular la inmunidad mediada por cadenas beta
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
US12076413B2 (en) 2020-10-28 2024-09-03 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity
WO2022175255A2 (en) 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
EP4637822A2 (en) * 2022-12-23 2025-10-29 The Wistar Institute of Anatomy and Biology Siglec 9 inhibitors and methods of use thereof for enhancing immunotherapy efficacy
AU2024379650A1 (en) * 2023-11-15 2026-06-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Trgv9 binding proteins and medical use thereof
WO2025220690A1 (ja) * 2024-04-17 2025-10-23 Meiji Seikaファルマ株式会社 T細胞腫瘍以外の悪性腫瘍患者に有効な二重特異性抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002351208A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
JP2012505654A (ja) * 2008-10-14 2012-03-08 ヤンセン バイオテツク,インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US10501540B2 (en) * 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
EP3560955A4 (en) * 2016-12-26 2020-12-23 Kyowa Kirin Co., Ltd. ANTIBODIES CAPABLE OF BINDING TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN
WO2019147735A1 (en) * 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
BR112020023508A2 (pt) * 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
JP7686571B2 (ja) * 2019-05-08 2025-06-02 ヤンセン バイオテツク,インコーポレーテツド T細胞媒介性免疫を調節するための材料及び方法
PE20231517A1 (es) * 2020-03-13 2023-09-28 Janssen Biotech Inc Materiales y metodos para la union de siglec-3/cd33

Also Published As

Publication number Publication date
CA3173268A1 (en) 2021-09-02
US20220306739A1 (en) 2022-09-29
IL295897A (en) 2022-10-01
WO2021173896A8 (en) 2022-10-06
TW202144415A (zh) 2021-12-01
JP2023515199A (ja) 2023-04-12
CN115484981A (zh) 2022-12-16
WO2021173896A1 (en) 2021-09-02
KR20220147631A (ko) 2022-11-03
AU2021225870A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
WO2021173896A8 (en) Materials and methods for modulating an immune response
PH12021552790A1 (en) Materials and methods for modulating t cell mediated immunity
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
PH12020551907A1 (en) Antagonizing cd73 antibody
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
MX2023002945A (es) Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas.
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
WO2021018859A3 (en) Antibodies binding to gprc5d
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
ZA202006318B (en) Anti-dll3 antibodies and uses thereof
MX2023002948A (es) Métodos y composiciones para modular la inmunidad mediada por cadena beta.
PH12022550693A1 (en) Multi-specific binding proteins for cancer treatment
PH12022553035A1 (en) Anti-phf-tau antibodies and uses thereof
ZA202110285B (en) Antibodies and methods of use
PH12021553197A1 (en) Anti-cd47 antibodies and uses thereof
MY210018A (en) Monoclonal antibody that binds specifically to gitr
MX2022007513A (es) Anticuerpos biespecificos con cisteinas intercatenarias apareadas alternativamente y sus usos.
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
WO2021226321A3 (en) Anti-tumor associated antigen antibodies and uses thereof
MX2025004782A (es) Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos
WO2021043810A8 (en) Anti-fucosyl-gm1 antibodies